FDA clears Pfizer’s PREVNAR 20 vaccine for IPD prevention
Pharmaceutical Technology
APRIL 28, 2023
The US Food and Drug Administration (FDA) has approved Pfizer’s 20-valent pneumococcal conjugate vaccine, PREVNAR 20 , to prevent invasive pneumococcal disease (IPD) in infants and children aged six weeks to 17 years. PREVNAR 20 has been developed on the basis of Pfizer’s approved PREVNAR 13 vaccine.
Let's personalize your content